On Thursday shares of Fuel Systems Solutions, Inc. (NASDAQ:FSYS) closed at $9.71. Company’s sales growth for last 5 years was -5.60% and EPS growth for next 5 years is recorded as 20.00%. Fuel Systems Solutions, Inc. (NASDAQ:FSYS) reported results for its first quarter ended March 31, 2015. Total revenue for the first quarter of 2015 was $63.3 million compared to $81.3 million for the first quarter of 2014. This variance includes the impact of foreign exchange on first quarter 2015 revenue, which was negative $9.3 million.
Merck & Co. Inc. (NYSE:MRK) in last trading activity moved up 0.07% to close at $60.30. Company weekly performance is 1.24% while its quarterly performance stands at 2.73%. Merck & Co. Inc. (NYSE:MRK) is -4.45% away from its 52 week high. Merck (NYSE:MRK), announced financial results for the first quarter of 2015. Non-GAAP (generally accepted accounting principles) earnings per share (EPS) of $0.85 for the first quarter exclude acquisition- and divestiture-related costs and restructuring costs.
On last trading day Jack in the Box Inc. (NASDAQ:JACK) moved up 2.06% to close at $90.73. Its volatility for the week is 2.61% while volatility for the month is 2.48%. JACK’s sales growth for past 5 years was -9.70% and its EPS growth for past 5 years was -0.10%. Jack in the Box Inc. (NASDAQ:JACK) monthly performance is -6.67%. Jack in the Box Inc. (NASDAQ:JACK) will report second quarter fiscal 2015 operating results after market close on Wednesday, May 13, 2015, and the company will host a conference call to review the results on Thursday, May 14, 2015, beginning at 8:30 a.m. PT. The call will be webcast live over the Internet.
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has 0.10% insider ownership while its institutional ownership stands at 91.80%. In last trading activity company’s stock closed at $21.11. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) , presented preclinical data demonstrating the feasibility of its proprietary DsiRNA-EX Conjugate-mediated delivery technology in enabling direct delivery of its RNAi-based investigational therapy to the liver via subcutaneous injection.
On last trading day UIL Holdings Corporation (NYSE:UIL) moved down -0.31% to close at $48.55. Its volatility for the week is 1.84% while volatility for the month is 1.68%. UIL’s sales growth for past 5 years was 12.70% and its EPS growth for past 5 years was 0.00%. UIL Holdings Corporation (NYSE:UIL) monthly performance is -4.82%. Equities researchers at Janney Montgomery Scott assumed coverage on shares of UIL Holdings (NYSE:UIL) in a research report issued on Tuesday. The firm set a “neutral” rating on the stock.